Diagnostics

Eupraxia EoE drug shows >90% inflammation cut in Phase 1b/2a data

EP-104GI reduced EoEHSS inflammation scores by more than 90% at the highest dose tested, with fibrosis improvements sustained to 36 weeks.
EP-104GI reduced EoEHSS inflammation scores by more than 90% at the highest dose tested, with fibrosis improvements sustained to 36 weeks.
The Biotech Times Editorial Team  · 
Diagnostics
Regulatory Science

EyePoint targets mid-2026 wet AMD readout as losses widen

EyePoint said its DURAVYU Phase 3 wet AMD trials remain on track for topline data from mid-2026, backed by $223m in cash extending into
EyePoint said its DURAVYU Phase 3 wet AMD trials remain on track for topline data from mid-2026, backed by $223m in cash extending into
The Biotech Times Editorial Team  · 
Diagnostics

Femasys logs first commercial use of FemaSeed Complete in OB/GYN offices

Femasys says its integrated intratubal insemination system has achieved its first revenue-generating use, positioning OB/GYNs as first-line fertility providers.
Femasys says its integrated intratubal insemination system has achieved its first revenue-generating use, positioning OB/GYNs as first-line fertility providers.
The Biotech Times Editorial Team  · 
Diagnostics

Glucotrack CBGM hits 6.8% MARD over 240 days in ovine study

A peer-reviewed ovine study shows Glucotrack's implantable glucose monitor maintained accuracy for up to 240 days with no device-related adverse events.
A peer-reviewed ovine study shows Glucotrack's implantable glucose monitor maintained accuracy for up to 240 days with no device-related adverse events.
The Biotech Times Editorial Team  · 
Bioprocessing
Diagnostics

ChemoMetec Q3 revenue rises 15% as XcytoMatic platform gains traction

The Danish cell-counting specialist reported DKK 142.3m in Q3 revenue, with XcytoMatic instrument sales quadrupling year-on-year, excluding a one-off accounting
The Danish cell-counting specialist reported DKK 142.3m in Q3 revenue, with XcytoMatic instrument sales quadrupling year-on-year, excluding a one-off accounting
The Biotech Times Editorial Team  · 
Biotech

Hemab Therapeutics prices upsized IPO at $18 per share on Nasdaq

The coagulation-disorder biotech raised approximately $301.5m gross, listing under ticker COAG with two clinical-stage antibody programmes in its pipeline.
The coagulation-disorder biotech raised approximately $301.5m gross, listing under ticker COAG with two clinical-stage antibody programmes in its pipeline.
The Biotech Times Editorial Team  · 
Regulatory Science

Immunocore posts $107m KIMMTRAK quarter with landmark five-year OS data

KIMMTRAK net sales grew 14% year-on-year in Q1 2026 as five-year trial data showed the drug doubled survival rates in metastatic uveal
KIMMTRAK net sales grew 14% year-on-year in Q1 2026 as five-year trial data showed the drug doubled survival rates in metastatic uveal
The Biotech Times Editorial Team  · 
Cell & Gene Therapy

IN8bio to present GBM clinical data and TCE platform at ASCO and R&D Day

IN8bio will showcase its gamma-delta T cell engager platform and new glioblastoma clinical data across four conferences in May and June 2026.
IN8bio will showcase its gamma-delta T cell engager platform and new glioblastoma clinical data across four conferences in May and June 2026.
The Biotech Times Editorial Team  · 
Biotech

InflaRx prices $150m share offering to fund complement pipeline

The Jena-based biopharmaceutical company sold 75 million ordinary shares at $2.00 each, attracting a broad syndicate of healthcare-focused institutional investors.
The Jena-based biopharmaceutical company sold 75 million ordinary shares at $2.00 each, attracting a broad syndicate of healthcare-focused institutional investors.
The Biotech Times Editorial Team  · 
Regulatory Science

Integra LifeSciences returns founder-era CEO Stuart Essig to top role

Integra LifeSciences has appointed chairman Stuart Essig as president and CEO, replacing Mojdeh Poul in a permanent leadership change effective 1 May 2026.
Integra LifeSciences has appointed chairman Stuart Essig as president and CEO, replacing Mojdeh Poul in a permanent leadership change effective 1 May 2026.
The Biotech Times Editorial Team  · 
Biotech

Integra LifeSciences posts Q1 revenue of $391.9m amid leadership change

The medical technology group beat its adjusted EPS guidance and named Stuart Essig as CEO as its Tissue Reconstruction unit led organic growth.
The medical technology group beat its adjusted EPS guidance and named Stuart Essig as CEO as its Tissue Reconstruction unit led organic growth.
The Biotech Times Editorial Team  · 
Bioprocessing

InterCure posts NIS 270m revenue in 2025 as war recovery accelerates

Israel's Canndoc parent reported 13% revenue growth and a twelfth consecutive half-year of positive Adjusted EBITDA as it rebuilt from the October 2023
Israel's Canndoc parent reported 13% revenue growth and a twelfth consecutive half-year of positive Adjusted EBITDA as it rebuilt from the October 2023
The Biotech Times Editorial Team  · 
Subscribe to